Preliminary study of fibrin glue combined with pingyangmycin for the treatment of venous malformations in the oral and maxillofacial region.
OBJECTIVE
To observe the outcome of using fibrin glue (FG) combined with Pingyangmycin (Tianjin Taihe Pharmaceutical Co Ltd, Tianjin, China) in the treatment of venous malformations (VMs) in the oral and maxillofacial region.


METHODS
The treatment data of 7 patients with VMs from January 2005 to January 2006 were reviewed. All these patients were injected with FG combined with Pingyangmycin. The vital signs and symptoms were observed and recorded immediately after injections. Radiographic examination was used for the evaluation of pulmonary conditions. The therapeutic effect was evaluated by clinical examination and Doppler ultrasonography. The follow-up time was from 1 to 2 years.


RESULTS
Of the 7 patients, 4 were male and 3 were female, with ages ranging from 10 to 62 years. Four of the 7 recovered to near-normal appearance, without any abnormal bloodstream detectable within the lesions. Two lesions were slightly asymmetrical in appearance, but no abnormal bloodstream could be detected in the lesions. Two patients had a fever during treatment, and one of them stopped treatment because of continuous high fever. No allergic reactions, pulmonary embolisms, or other complications were found during or after treatment.


CONCLUSIONS
The therapeutic modality of FG combined with Pingyangmycin for VMs in the oral and maxillofacial region was effective, and the extent of morbidity was acceptable. However, the further long-term observation of severe complications such as deep venous thrombosis and pulmonary embolism should be performed in additional biological and clinical studies.
Yang
Yaowu
Y
Department of Oral and Maxillofacial Surgery, School of Stomatology, Fourth Military Medical University, Xi'an, China. yangyaowu_1@sina.com
Sun
Moyi
M
Hou
Rui
R
Yan
Zhiwei
Z
Wang
Lei
L
Cheng
Xiaobing
X
Lei
Delin
D
Liu
Yanpu
Y
D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001165:Arteriovenous Malformations / Q000000981:diagnostic imaging / Q000628:therapy*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002648:Child; D004338:Drug Combinations; D005153:Facial Neoplasms / Q000628:therapy*; D005260:Female; D015718:Fibrin Tissue Adhesive / Q000008:administration & dosage*; D006392:Hemangioma, Cavernous / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D015552:Injections, Intralesional; D018810:Magnetic Resonance Angiography; D008297:Male; D009062:Mouth Neoplasms / Q000628:therapy*; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler
D000903:Antibiotics, Antineoplastic; D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive; D012597:Sclerosing Solutions; D001761:Bleomycin; C025703:bleomycetin